All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Recovery comparison

BPC-157 vs Larazotide

An educational, source-based comparison of BPC-157 and Larazotide — how each peptide works, what it's researched for, and what to know before going deeper.

Tissue Repair · Gastrointestinal
BPC-157

Body Protection Compound studied for gut and tissue support.

Mechanism

A pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Research suggests it modulates the nitric oxide system, upregulates growth hormone receptors in injured tissue, and promotes angiogenesis (formation of new blood vessels) — mechanisms associated with accelerated tendon, ligament, muscle, and intestinal mucosa repair in preclinical models.

Research areas
  • Tendon-to-bone healing
  • Ligament and muscle recovery
  • Gastric ulcer protection
  • Inflammatory bowel models
  • Neuroprotection (rodent)
Considerations
  • Human clinical trials are limited — most research is preclinical.
  • Not FDA-approved for human therapeutic use.
  • Quality, purity, and dosing of compounded peptides vary widely.
Full BPC-157 profile →
Gastrointestinal · Barrier
Larazotide

Tight junction regulator studied for celiac disease.

Mechanism

An octapeptide zonulin antagonist that helps maintain intestinal tight junction integrity, reducing paracellular permeability triggered by gluten in celiac disease.

Research areas
  • Celiac disease (Phase 3 completed)
  • Intestinal barrier function ('leaky gut' research)
  • Environmental enteropathy
Considerations
  • Not yet FDA-approved.
  • Investigational; physician oversight required.
Full Larazotide profile →

BPC-157 vs Larazotide — Key differences

  • Class: BPC-157 is classified as Tissue Repair · Gastrointestinal, while Larazotide is Gastrointestinal · Barrier.
  • Primary research focus: BPC-157tendon-to-bone healing; Larazotideceliac disease (phase 3 completed).
  • Tag: Recovery vs Gut.

Related comparisons